CME CME Groupdata gap · 91% coverage
Financials · Financial Exchanges & Data · close $293.87 (2026-10-16) · latest quarter in EDGAR: 2026-06-30
CME Group (CME) has a ThetaGrade House Rating of 53/100 (grade C), ranking #6 of 38 in Financials. Its strongest pillars are profitability (100) and balance sheet (66); its weakest is valuation (20). Data gap: 1 factor without usable data, so 91% of the method weight is covered. TTM revenue growth is 5.1% and operating margin 65.1%.
Data as of .
Data gap
No usable data for: 4Q gross-margin change. Data gap: no usable data for this factor, so it is left out and its weight is shared among the factors that do have data (no value is imputed). 91% of the full method weight is backed by data.
Analyst sentiment
weight 7.5% · 50| Consensus score (1–5) (3.8%) | derived | 25 |
| 90-day net rating shift (3.8%) | derived | 54 |
Growth
weight 30.83% · 25| Revenue growth YoY (TTM) (12.3%) | 5.1% | 22 |
| EPS growth YoY (TTM) (12.3%) | 14.1% | 40 |
| Revenue acceleration (6.2%) | -13.6% | 3 |
Profitability
weight 18.5% · 100| Operating margin (18.5%) | 65.1% | 100 |
| 4Q gross-margin change (0.0%)data gap | — | — |
Balance sheet
weight 18.5% · 66| Net debt / EBITDA (9.9%) | -0.47× | 82 |
| Current ratio (4.9%) | 1.02 | 27 |
| Interest coverage (3.7%) | 25.43× | 77 |
Cash flow
weight 12.33% · 65| FCF margin (6.2%) | 64.3% | 100 |
| FCF yield (6.2%) | 4.0% | 30 |
Valuation
weight 12.33% · 20| P/E (inverted) (6.2%) | 24.93× | 33 |
| EV/Sales (inverted) (6.2%) | 15.33× | 6 |
Technicals (EOD)
| RSI(14) | 71.3 |
| EMA 9 / 21 | 281.90 / 276.59 |
| 200-day SMA | 278.69 |
| Volume vs 20d avg | 1.16× |
| 20-day return | 8.4% |
Exit-rule monitor
- EXITRating break: House Rating below 60
Data source per metric (SEC XBRL tag or derivation): Revenue: Revenues · Operating income: OperatingIncomeLoss · Interest expense: InterestAndDebtExpense · D&A: DepreciationAndAmortization · EPS: EarningsPerShareDiluted · Market cap: SEC shares (us-gaap weighted basic shares, latest quarter (proxy)) × EOD close · P/E: EOD close ÷ SEC TTM EPS (EarningsPerShareDiluted).
Get rating changes like CME's in the free Daily Brief
The market’s key events and signals, digested before the open.
- ✓ Pre-market Daily Brief: events, headlines, rating changes (2-min read)
- ✓ Sunday: Top 5 Weekly Picks, exit alerts, CSP put watchlist
- ✓ OPEX, FOMC, CPI and jobs-day reminders
Free. Want more? See Premium (waitlist).
FAQ
- What is CME's House Rating?
- CME scores 53 out of 100 (grade C) as of 2026-10-16, ranking #6 of 38 Financials stocks we cover.
- What do analysts say about CME?
- ThetaGrade's analyst-sentiment pillar for CME scores 50/100 against its sector peers, which we read as mixed. This is our own derived score; we do not republish individual analyst ratings, counts or targets.
- When does CME report earnings next?
- CME's next earnings report is estimated for about 2026-10-21 (window 2026-10-14 to 2026-10-31), based on its past SEC 8-K earnings filings. This is an estimate, not a company-confirmed date.
- Is CME a buy?
- ThetaGrade does not give personal advice. The House Rating is an educational, rules-based summary of public data; see the methodology for how it is built.
Sources: SEC EDGAR filings (fetched 2026-10-18), Finnhub recommendation trends, Massive EOD prices. Scores are sector percentiles; a factor without usable data is a data gap: it is left out and the remaining weights are renormalized (nothing is imputed). Educational only. Methodology